U.S. markets open in 9 hours 26 minutes
  • S&P Futures

    4,323.75
    -0.50 (-0.01%)
     
  • Dow Futures

    33,616.00
    -22.00 (-0.07%)
     
  • Nasdaq Futures

    14,985.50
    +0.75 (+0.01%)
     
  • Russell 2000 Futures

    1,769.80
    -1.60 (-0.09%)
     
  • Crude Oil

    88.13
    -0.69 (-0.78%)
     
  • Gold

    1,834.40
    -12.80 (-0.69%)
     
  • Silver

    21.05
    -0.37 (-1.73%)
     
  • EUR/USD

    1.0472
    -0.0009 (-0.08%)
     
  • 10-Yr Bond

    4.6830
    +0.1100 (+2.41%)
     
  • Vix

    17.61
    +0.09 (+0.51%)
     
  • GBP/USD

    1.2078
    -0.0011 (-0.09%)
     
  • USD/JPY

    149.8470
    +0.0120 (+0.01%)
     
  • Bitcoin USD

    27,607.31
    -518.30 (-1.84%)
     
  • CMC Crypto 200

    590.33
    -13.21 (-2.19%)
     
  • FTSE 100

    7,510.72
    -97.36 (-1.28%)
     
  • Nikkei 225

    31,349.42
    -410.46 (-1.29%)
     

Sage Therapeutics to Present at Upcoming May Investor Conferences

CAMBRIDGE, Mass., May 03, 2023--(BUSINESS WIRE)--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will present at the following upcoming investor conferences in May:

  • BofA Securities 2023 Health Care Conference (Las Vegas, NV): presentation on Wednesday, May 10, 2023 at 2:20 p.m. PT.

  • 2023 RBC Capital Markets Global Healthcare Conference (New York, NY): fireside chat on Wednesday, May 17, 2023 at 11:30 a.m. ET.

A live webcast of each event can be accessed on the Investor page of Sage’s website at investor.sagerx.com. A replay of the webcasts will be available following the completion of the event and will be archived for up to 30 days.

About Sage Therapeutics

Sage Therapeutics is a biopharmaceutical company fearlessly leading the way to create a world with better brain health. Our mission is to pioneer solutions to deliver life-changing brain health medicines, so every person can thrive. For more information, please visit www.sagerx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230502005905/en/

Contacts

Investor:
Helen Rubinstein
315-382-3979
helen.rubinstein@sagerx.com

Media:
Matthew Henson
917-930-7147
matthew.henson@sagerx.com